4.7 Article

A dual drug delivery platform based on thermo-responsive polymeric micelle capped mesoporous silica nanoparticles for cancer therapy

Journal

MICROPOROUS AND MESOPOROUS MATERIALS
Volume 338, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.micromeso.2022.111943

Keywords

Tumor therapy; Capping gatekeeper; Mesoporous silica; Polymer micelles; Thermo-sensitive

Funding

  1. National Natural Science Foundation of China [51803174]

Ask authors/readers for more resources

The combination of organic polymers and inorganic nanoparticles to design intelligent nanocarriers is important for delivering anticancer drugs to tumor cells effectively. In this study, a thermo-responsive micelle was prepared as a gatekeeper attached to the surface of mesoporous silica nanoparticle through disulfide bonds. The dual drug delivery platform showed controllable release of drugs and demonstrated high cytocompatibility and cytotoxicity against cancer cells.
The combination of organic polymers and inorganic nanoparticles to design intelligent nanocarriers is of great significance for effective delivery of anticancer drugs to tumor cells for therapy. Herein, we have prepared a thermo-responsive micelle as a gatekeeper to attach on the surface of mesoporous silica nanoparticle (MSN) through disulfide bonds. DOX was encapsulated in both nanocarriers, resulting in a pH/redox/temperature responsive dual drug delivery platform (DOX@MSN-S-2-F127-PCL@DOX, abbreviated as DMSFPD) with high loading capacity and excellent stimuli-responsive performance for cancer therapy. The cumulative release curve in vitro indicated that DOX could be controllably released from DMSFPD. With the elevated temperature at 40 ?, the uncapping ofF127-PCL250 (FP250) micelle from MSN after GSH stimulus and the shrinkage of FP250 micelle caused a fast release of DOX from both MSN and micelle, which greatly increased the drug concentration immediately. The intracellular uptake and cytocompatibility demonstrated that MSN-S-2-F127-PCL250 (MSFP250) could be efficiently endocytosed and have shown favorable biocompatibility in both normal and tumoral cells. Cytotoxicity results illustrated that DMSFPD could significantly kill different kinds of cancer cells. Therefore, this dual drug delivery capping platform provides a new and promising strategy for cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available